FREISING, Germany--(BUSINESS WIRE)--Pieris AG has achieved the third milestone for its lead Anticalin® program with Daiichi Sankyo Company Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo, TSE 4568), triggering an undisclosed payment, the company announced today. This milestone marks in total the fourth milestone achieved for the parties’ two R&D collaborative projects. Specifically, the milestone achieved was the progression of an Anticalin drug candidate through a non-GLP toxicity study in non-human primates. In 2013, Pieris transferred the program to Daiichi Sankyo, which successfully carried out this study.
Help employers find you! Check out all the jobs and post your resume.
